Efficacy of praziquantel on Schistosoma haematobium and re-infection rates among school-going children in the Ndumo area of uMkhanyakude district, KwaZulu-Natal, South Africa

BACKGROUND: Despite its low cure rates and possible resistance, praziquantel (PZQ) is the only drug available for schistosomiasis treatment. Hence, monitoring its efficacy is crucial. This study assessed the efficacy of PZQ, determined re-infection and incidence rates of Schistosoma haematobium infe...

Descripción completa

Detalles Bibliográficos
Autores principales: Kabuyaya, Muhubiri, Chimbari, Moses John, Manyangadze, Tawanda, Mukaratirwa, Samson
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5383960/
https://www.ncbi.nlm.nih.gov/pubmed/28385154
http://dx.doi.org/10.1186/s40249-017-0293-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5383960/
https://www.ncbi.nlm.nih.gov/pubmed/28385154
http://dx.doi.org/10.1186/s40249-017-0293-3

Ejemplares similares